Axonics, Inc. (NASDAQ:AXNX) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its position in Axonics, Inc. (NASDAQ:AXNX) by 23.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,760 shares of the company’s stock after acquiring an additional 1,270 shares during the period. Victory Capital Management Inc.’s holdings in Axonics were worth $421,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of AXNX. RiverPark Advisors LLC grew its position in Axonics by 14.4% during the fourth quarter. RiverPark Advisors LLC now owns 1,185 shares of the company’s stock valued at $74,000 after buying an additional 149 shares during the period. Arizona State Retirement System increased its holdings in shares of Axonics by 2.2% in the third quarter. Arizona State Retirement System now owns 14,345 shares of the company’s stock valued at $805,000 after purchasing an additional 311 shares during the last quarter. Hedges Asset Management LLC raised its holdings in shares of Axonics by 6.5% during the 4th quarter. Hedges Asset Management LLC now owns 8,600 shares of the company’s stock worth $535,000 after acquiring an additional 525 shares during the period. Diversified Trust Co raised its stake in Axonics by 4.2% during the fourth quarter. Diversified Trust Co now owns 12,967 shares of the company’s stock worth $807,000 after purchasing an additional 525 shares during the period. Finally, C M Bidwell & Associates Ltd. raised its position in shares of Axonics by 108.2% during the 3rd quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company’s stock valued at $71,000 after buying an additional 660 shares during the period. Hedge funds and other institutional investors own 99.48% of the company’s stock.

Analyst Ratings Changes

AXNX has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research report on Monday, May 6th. Royal Bank of Canada reissued a “sector perform” rating and set a $71.00 price objective on shares of Axonics in a research report on Thursday, February 29th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $70.30.

Axonics Price Performance

Shares of NASDAQ:AXNX opened at $67.22 on Friday. The stock has a market cap of $3.43 billion, a P/E ratio of -210.06 and a beta of 0.60. Axonics, Inc. has a 1-year low of $47.59 and a 1-year high of $69.68. The firm has a fifty day moving average price of $67.69 and a 200 day moving average price of $64.80.

Axonics (NASDAQ:AXNX) last announced its quarterly earnings data on Tuesday, April 30th. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.32). The firm had revenue of $91.41 million for the quarter, compared to analysts’ expectations of $89.79 million. Axonics had a negative return on equity of 2.58% and a negative net margin of 4.12%. The firm’s quarterly revenue was up 29.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.19) EPS. Sell-side analysts expect that Axonics, Inc. will post 0.13 EPS for the current fiscal year.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.